my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
12-12-2007: GE Healthcare, a unit of General Electric Company, and Novavax Inc. announced a collaboration agreement to develop and market a pandemic influenza vaccine manufacturing solution for selected international countries. This collaboration leverages GE Healthcare's bioprocess solutions and design expertise and Novavax's virus-like particle (VLP) and manufacturing platform.
"This collaboration is a great first example of GE Healthcare realizing its strategy of enabling affordable and safe vaccine production for countries that need to better prepare for emerging infectious diseases," said Peter Ehrenheim, President and CEO, GE Healthcare Life Sciences.
Novavax's VLP-based H5N1 pandemic flu vaccine is currently in Phase I/IIa clinical trials. The goal is that any required recombinant vaccine could be produced in cell culture within 12 weeks of identification of a pandemic strain, without using eggs or live influenza virus - as little as half the time compared with currently available processes.
Commenting on the collaboration, Dr. Rahul Singhvi, President and CEO of Novavax said, "This collaboration is a critical milestone in addressing one of the most pressing global healthcare issues of the 21st century. We believe the combination of these technologies will enable the
creation of a country's rapid response supply and self-sufficiency in
pandemic flu vaccine."
Watchlist
This is where you can add this news to your personal favourites
VTT and GE Healthcare developing novel biomarkers to predict Alzheimer’s disease
Scientists from VTT Technical Research Centre of Finland in collaboration with the University of Eastern Finland have recently discovered a serum biochemical signature which predicts progression to Alzheimer’s disease months or even years before the first symptoms of the disease occur. The ... more
GE Healthcare Life Sciences completes acquisition of Xcellerex, Inc.
GE Healthcare announced that it has completed the acquisition of Xcellerex, Inc., a supplier of manufacturing technologies for the fast-growing biopharmaceutical industry. The acquisition expands GE Healthcare’s offering of technologies and services for the manufacture of biopharmaceuticals ... more
GE Healthcare and BAC collaborate to launch new bioprocess affinity resin
GE Healthcare and BAC BV announced that, following a successful collaboration between the two companies, GE Healthcare Life Sciences has added a new affinity resin to its portfolio of technologies for the purification of antibody-based fragments. GE Healthcare’s new resin, LambdaFabSelect, ... more
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutica ... more
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutica ... more
GE Launches $250 Million Healthymagination Fund
GE announced the formation of the “GE Healthymagination Fund”, a new equity fund that will make investments in highly promising healthcare technology companies. The fund will invest in companies globally that have innovative diagnostic, IT, and life sciences technologies aligned with the s ... more
Quotient Bioresearch acquires radiochemical custom synthesis operations from GE Healthcare
Quotient Bioresearch Limited announced that it has reached an agreement to acquire Amersham Radiolabelling Services, the radiochemical custom synthesis operations of GE Healthcare. This represents Quotient’s seventh acquisition since its formation in early 2007. According to the company, t ... more
GE Healthcare Forms Strategic Alliance with FUJIFILM in Life Sciences
GE Healthcare, a unit of General Electric Company, announced that it has entered into a Strategic Alliance Agreement with FUJIFILM Corporation. Under the alliance, Fujifilm will develop, manufacture and supply advanced biomolecular imaging systems to GE Healthcare. The products will be sold ... more
Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico
Novavax, Inc. announced that it has initiated a two-stage clinical study of its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare. Avimex is providing financial support for the trial and is expected to distribute ... more
Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Novavax, Inc. announced favorable results from the second stage of the Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate. The vaccine, which does not contain an adjuvant, induced robust neutralizing antibody responses. Novavax's VLP candi ... more
GE Healthcare and Novavax establish collaboration to develop and market pandemic influenza solution
GE Healthcare, a unit of General Electric Company, and Novavax Inc. announced a collaboration agreement to develop and market a pandemic influenza vaccine manufacturing solution for selected international countries. This collaboration leverages GE Healthcare's bioprocess solutions and desig ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
